United States Prescription Drugs Market is expected to reach US$ 2,151.6 billion by 2032 | Top key players - F. Hoffmann-La Roche Ltd, Mylan N.V., Sanofi.

Market Size and Growth:

The Global Prescription Drugs Market size reached US$ 1,162.6 billion in 2023 and is expected to reach US$ 2,151.6 billion by 2032, growing with a CAGR of 7.1% during the forecast period 2024-2032. The Market is driven by rising chronic disease prevalence, increasing healthcare spending, and continuous innovation in drug development and biotechnology.

To Download a Free Sample PDF (Use Corporate email ID to Get Higher Priority) at: https://datamintelligence.com/download-sample/prescription-drugs-market?sz

The Prescription Drugs Market encompasses medications that require authorization from a licensed healthcare provider before being dispensed. These drugs are used to treat, manage, and prevent various diseases and medical conditions. The market includes branded and generic pharmaceuticals, driven by factors such as rising healthcare needs, technological advancements, and growing prevalence of chronic illnesses.

Industry Recent Developments:

United States:

✅ October 2025: The U.S. administration implemented a 100% tariff on imported branded prescription drugs to encourage domestic manufacturing, requiring pharmaceutical companies to build or expand manufacturing plants in the U.S. to avoid these tariffs.

✅ October 2025: Multiple major pharmaceutical companies launched direct-to-consumer drug sales platforms and announced prescription drug price cuts in response to government efforts to bypass traditional pharmacy benefit managers and lower patient costs.

✅ August-October 2025: Growth in prescription drug expenditures remained robust, driven by the introduction of new specialty drugs (especially in cancer and endocrinology) and increased utilization. Policy changes and the entry of innovative therapies contributed to a national prescription spending growth estimate of 9% to 11% for the year.

Japan:

✅ August-October 2025: The Japanese government accelerated efforts to boost generic drug usage by offering incentives and promoting mergers among pharmaceutical firms to stabilize supply and reduce healthcare costs, with generics gaining significant market share.

✅ August-October 2025: Rapid uptake of biosimilars was noted, especially in oncology, supported by premium adjustments and new reimbursement incentives that increased monthly prescription rates for these lower-cost alternatives.

✅ August-October 2025: Foreign pharmaceutical companies' prescription drug sales in Japan were projected to rise by 1.8% for the year, reflecting stable demand for both innovative and generic medicines as regulatory and pricing reforms continue to reshape the market.

Get Customization in the report as per your requirements + Exclusive Bundle & Multi-User Discounts: https://datamintelligence.com/customize/prescription-drugs-market?sz

FDA Approvals (2025) - Highlights:

✅ FDA novel drug approvals (2025) - list of new molecular entities / novel biologics approved in 2025 (official FDA compilation).

✅ Keytruda (pembrolizumab) - subcutaneous formulation (Keytruda Qlex): FDA approved Merck's subcutaneous version in Sept 2025 - important because it increases patient convenience and helps Merck defend market share ahead of patent cliffs.

✅ Several oncology and orphan approvals during 2025 (including combination and formulation approvals such as nivolumab + ipilimumab for HCC and other orphan indications across the year) - FDA oncology approval notices and orphan/PD­UFA lists reflect these additions.

Major Mergers & Acquisitions (2025) - selected big deals:

✅ Johnson & Johnson - acquisition of Intra-Cellular Therapies (~$14.6B) (2025): one of the largest pharma deals of the year, expanding J&J's CNS / mental-health portfolio.

✅ Torrent Pharma: move to acquire controlling stake in JB Chemicals (from KKR) - large India-market consolidation (deal announced in 2025).

✅ Other notable 2025 M&A activity: multiple strategic buys across mid-cap biotechs (Jazz/Chimerix, Novo Nordisk activity in metabolic space, several $1-5B strategic deals). Market summaries and deal trackers list the top transactions.

Regulatory Approvals:

✅ European Medicines Agency (EMA) - ongoing approvals & CHMP evaluations in 2025: EMA maintained an active pipeline of approvals and CHMP opinions in 2025 (new medicines and biosimilars through the year). Several medicines approved in the EU during 2025 overlapped with FDA activity but with differing timing or indications.

✅ Peer-review summaries (Lancet / specialty journals) track EMA approvals and biosimilar authorisations during 2025 (useful for cross-market regulatory comparisons)

Major Key Players:

F. Hoffmann-La Roche Ltd
Mylan N.V.
Teva Pharmaceutical Industries Ltd
Sanofi
Pfizer Inc
GlaxoSmithKline plc
Novartis AG
Merck & Co., Inc.
Allergan
Dr. 'Reddy's Laboratories Ltd.

Segments Covered in the Prescription Drugs Market:

By Type: Branded, Generic.

By Therapy Area: Oncology, Immunology, Ophthalmology, Respiratory, Gastroenterology, Gynecology, Others.

By Route of Administration: Oral, Topical, Parenteral, Others.

Regional Analysis for Prescription Drugs Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Looking For Full Report? Get it Here: https://www.datamintelligence.com/buy-now-page?report=prescription-drugs-market

Chapter Outline:

⏩ Market Overview: It contains five chapters, as well as information about the research scope, major manufacturers covered, market segments, Prescription Drugs market segments, study objectives, and years considered.

⏩ Market Landscape: The competition in the Global Prescription Drugs Market is evaluated here in terms of value, turnover, revenues, and market share by organization, as well as market rate, competitive landscape, and recent developments, transaction, growth, sale, and market shares of top companies.

⏩ Companies Profiles: The global Prescription Drugs market's leading players are studied based on sales, main products, gross profit margin, revenue, price, and growth production.

⏩ Market Outlook by Region: The report goes through gross margin, sales, income, supply, market share, CAGR, and market size by region in this segment. North America, Europe, Asia Pacific, Middle East & Africa, and South America are among the regions and countries studied in depth in this study.

⏩ Market Segments: It contains the deep research study which interprets how different end-user/application/type segments contribute to the Prescription Drugs Market.

⏩ Market Forecast: Production Side: In this part of the report, the authors have focused on production and production value forecast, key producers forecast, and production and production value forecast by type.

⏩ Research Findings: This section of the report showcases the findings and analysis of the report.

⏩ Conclusion: This portion of the report is the last section of the report where the conclusion of the research study is provided.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Frequently asked questions:

➠ What is the global sales value, production value, consumption value, import and export of Prescription Drugs market?

➠ Who are the global key manufacturers of the Prescription Drugs Industry? How is their operating situation (capacity, production, sales, price, cost, gross, and revenue)?

➠ What are the Prescription Drugs market opportunities and threats faced by the vendors in the global Prescription Drugs Industry?

➠ Which application/end-user or product type may seek incremental growth prospects? What is the market share of each type and application?

➠ What focused approach and constraints are holding the Prescription Drugs market?

➠ What are the different sales, marketing, and distribution channels in the global industry?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.